<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473417</url>
  </required_header>
  <id_info>
    <org_study_id>DA2811_BE_I</org_study_id>
    <nct_id>NCT04473417</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects</brief_title>
  <acronym>DA-2811</acronym>
  <official_title>An Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2811 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the phase I study to evaluate the pharmacokinetics and safety of DA-2811 and Forxiga®
      after a single oral dose in healthy volunteers.

      The study will also compare the pharmacokinetics and safety profiles of DA-2811 under fasting
      and fed states in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>pre-dose~48 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to time the last quantifiable time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>pre-dose~48 hours post-dose</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0 - ∞)</measure>
    <time_frame>pre-dose~48 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve from time zero to extrapolated infinite time (0 - ∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>pre-dose~48 hours post-dose</time_frame>
    <description>Time to reach maximum plasma concentration following drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>pre-dose~48 hours post dose</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A, Sequence I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: Forxiga® 10mg → DA-2811, Period II: DA-2811 → Forxiga® 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Sequence II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: DA-2811 → Forxiga® 10mg, Period II: Forxiga® 10mg → DA-2811</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Sequence I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: DA-2811 under fasting state → DA-2811 under fed state, Period II:DA-2811 under fed state → DA-2811 under fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Sequence II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: DA-2811 under fed state → DA-2811 under fasting state, Period II: DA-2811 under fasting state → DA-2811 under fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forxiga 10mg</intervention_name>
    <description>single dose administration after 10hr fasting</description>
    <arm_group_label>Part A, Sequence I</arm_group_label>
    <arm_group_label>Part A, Sequence II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-2811</intervention_name>
    <description>single dose administration after 10hr fasting</description>
    <arm_group_label>Part A, Sequence I</arm_group_label>
    <arm_group_label>Part A, Sequence II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-2811</intervention_name>
    <description>single dose administration after 10hr fasting</description>
    <arm_group_label>Part B, Sequence I</arm_group_label>
    <arm_group_label>Part B, Sequence II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-2811</intervention_name>
    <description>single dose administration after high fat and calorie fed diet</description>
    <arm_group_label>Part B, Sequence I</arm_group_label>
    <arm_group_label>Part B, Sequence II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects

          -  BMI between 18.5 and 29.9 kg/m2 and weigh at least 50 kg

          -  Volunteer who totally understands the progress of this clinical trial, make decision
             by his or her free will, and signed a consent form to follow the progress.

        Exclusion Criteria:

          -  Volunteer who has present or past history of clinically significant cardiovascular,
             respiratory, urinary, gastrointestinal, hepatic, renal, skin, immunological,
             musculoskeletal, endocrinal, neurological, psychiatric and/or hematological disease

          -  Vulnerable to dehydration due to poor oral intake or clinically significant
             dehydration as judged by the investigator

          -  History of gastrointestinal disease or any gastrointestinal surgery(except for simple
             appendectomy, hernia surgery, hemorrhoid surgery)

          -  History of diseases that may impact absorption, distribution, metabolism, and
             excretion of the study drugs.

          -  Hypersensitivity to a drug containing an ingredient of the investigational product,
             Sodium glucose transporter-2 inhibitors, additional ingredient or other drugs (e.g.,
             aspirin, antibiotics, etc.) or medical history of clinically significant
             hypersensitivity.

          -  History of clinically significant active chronic disease

          -  volunteer who has genetic disorder like lapp lactase deficiency or glucose-galactose
             malabsorption.

          -  History of clinically significant allergies including drug allergies

          -  History of drug abuse or addicted

          -  Clinical laboratory test values are outside the accepted normal range

          -  Participation in another clinical trial within 6 months of the first IP administration

          -  Sexually active women of childbearing potential not consistently and correctly
             practicing birth control by dual contraceptive method until 2 months after last IP
             administration

          -  Breast-feeding period, pregnant, or positive to urine pregnancy test (conducted before
             the first drug administration)

          -  Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JaeYong Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bundang Seoul National University Hospital Clinical Trial Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung</last_name>
    <phone>02-920-8369</phone>
    <email>jhsung@donga.co.kr</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

